Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR), 'Accelerated Approval May Be In The Cards'
Tweet Send to a Friend
Oppenheimer analyst Leland Gershall reiterated an Outperform rating and $15.00 price target on Capricor Therapeutics (NASDAQ: CAPR).The analyst commented: "Tomorrow ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
